R
Ryan Rodriguez
Researcher at Genentech
Publications - 3
Citations - 158
Ryan Rodriguez is an academic researcher from Genentech. The author has contributed to research in topics: Cytotoxic T cell & CD8. The author has an hindex of 3, co-authored 3 publications receiving 89 citations.
Papers
More filters
Journal ArticleDOI
Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Huizhong Xiong,Stephanie Mittman,Ryan Rodriguez,Marina Moskalenko,Patricia Pacheco-Sanchez,Yagai Yang,Dorothee Nickles,Rafael Cubas +7 more
TL;DR: These results demonstrate that anti-PD-L1 treatment can favorably remodel the macrophage compartment in responsive tumor models toward a more proinflammatory phenotype, mainly through increased IFNγ levels and suggest that directly targeting these cells with reprogramming and depleting agents may further augment the breadth and depth of response to anti- PD- L1 treatment in less responsive or more macrophages-dense tumor microenvironments.
Journal ArticleDOI
Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Huizhong Xiong,Stephanie Mittman,Ryan Rodriguez,Patricia Pacheco-Sanchez,Marina Moskalenko,Yagai Yang,Justin Elstrott,Alex T. Ritter,Sören Müller,Dorothee Nickles,Teresita L. Arenzana,Aude-Hélène Capietto,Lélia Delamarre,Zora Modrusan,Sascha Rutz,Ira Mellman,Rafael Cubas +16 more
TL;DR: It is reported that among CD8+ T cells in commonly used syngeneic tumor models, the coexpression of inhibitory receptors PD-1, LAG3, and TIM3 defined a group of highly activated and functional effector cells in syngenetic tumor models.
Journal ArticleDOI
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
Rafael Cubas,Zia Khan,Qian Gong,Marina Moskalenko,Huizhong Xiong,Qinglin Ou,Christine Pai,Ryan Rodriguez,Jeanne Cheung,Andrew C. Chan +9 more
TL;DR: It is demonstrated that the autoimmune susceptibility Ptpn22(C1858T) variant is associated with lower risk of developing non-melanoma skin cancers, improved overall survival and increased risk for development of hyperthyroidism or hypothyroidism following atezolizumab (anti-PD-L1) treatment.